Ultrafiltration Versus IV Diuretics in Worsening Heart Failure

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 167 participants.

Also called NCT05318105

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 167 participants (enrolled count) (from the registry)
Sponsor
Nuwellis, Inc. (from the registry)
Registry
  • NCT NCT05318105
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05318105. Randomized; no masking; primary purpose treatment. Start 2022-06-28 (actual); primary completion 2025-10-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
Acronym
REVERSE-HF
Condition
Heart Failure (for Example, Fluid Overload)
Condition
Heart Failure
Condition
Fluid Overload
Intervention (Device)
Aquadex Smartflow® System
Intervention (Drug)
IV Loop Diuretics
Lead sponsor
Nuwellis, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05318105
Content hash
1f21c9da361ec435c988de015e356a69ef9586b6a556abcd84c09700739bc322